Notice: This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends MGEN vs. PSNL, SERA, BDSX, ENZ, XGN, BNR, RNLX, PMD, BGLC, and MDXHShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Personalis (PSNL), Sera Prognostics (SERA), Biodesix (BDSX), Enzo Biochem (ENZ), Exagen (XGN), Burning Rock Biotech (BNR), Renalytix (RNLX), Psychemedics (PMD), BioNexus Gene Lab (BGLC), and MDxHealth (MDXH). Miragen Therapeutics vs. Personalis Sera Prognostics Biodesix Enzo Biochem Exagen Burning Rock Biotech Renalytix Psychemedics BioNexus Gene Lab MDxHealth Miragen Therapeutics (NASDAQ:MGEN) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation. Which has more volatility & risk, MGEN or PSNL? Miragen Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Does the MarketBeat Community favor MGEN or PSNL? Miragen Therapeutics received 153 more outperform votes than Personalis when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 66.28% of users gave Personalis an outperform vote. CompanyUnderperformOutperformMiragen TherapeuticsOutperform Votes26770.45% Underperform Votes11229.55% PersonalisOutperform Votes11466.28% Underperform Votes5833.72% Do institutionals & insiders have more ownership in MGEN or PSNL? 61.9% of Personalis shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is MGEN or PSNL more profitable? Personalis has a net margin of -101.78% compared to Miragen Therapeutics' net margin of -1,393.50%. Personalis' return on equity of -56.87% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Miragen Therapeutics-1,393.50% -141.66% -88.74% Personalis -101.78%-56.87%-35.08% Which has better valuation & earnings, MGEN or PSNL? Miragen Therapeutics has higher earnings, but lower revenue than Personalis. Personalis is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiragen Therapeutics$4.46M20.01-$41.87M-$20.09-1.14Personalis$73.48M3.61-$108.30M-$1.64-3.05 Do analysts recommend MGEN or PSNL? Personalis has a consensus price target of $6.81, suggesting a potential upside of 36.25%. Given Personalis' higher possible upside, analysts plainly believe Personalis is more favorable than Miragen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Miragen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/APersonalis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer MGEN or PSNL? In the previous week, Personalis had 2 more articles in the media than Miragen Therapeutics. MarketBeat recorded 2 mentions for Personalis and 0 mentions for Miragen Therapeutics. Personalis' average media sentiment score of 0.23 beat Miragen Therapeutics' score of 0.00 indicating that Personalis is being referred to more favorably in the news media. Company Overall Sentiment Miragen Therapeutics Neutral Personalis Neutral SummaryPersonalis beats Miragen Therapeutics on 12 of the 17 factors compared between the two stocks. Ad WealthPressCould TSLA reach $500 a share? Free ebook says it’s possible.Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.To claim your copy, follow this link Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.26M$2.58B$5.06B$8.43BDividend YieldN/A1.72%7.52%4.16%P/E Ratio-2.1534.73131.9616.70Price / Sales20.01264.081,683.8276.34Price / CashN/A497.7737.1533.56Price / Book3.374.524.614.98Net Income-$41.87M-$31.39M$115.40M$224.69M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$22.84+2.5%N/A+46.7%$89.26M$4.46M-2.1545High Trading VolumePSNLPersonalis4.0778 of 5 stars$5.05-2.7%$6.81+34.9%+346.4%$262.29M$80.03M-3.08400Upcoming EarningsSERASera Prognostics0.0762 of 5 stars$7.69-5.5%N/A+311.9%$256.61M$107,000.00-7.85120Upcoming EarningsBDSXBiodesix3.4521 of 5 stars$1.70+2.4%$3.06+80.0%-13.1%$246.80M$60.90M-3.70220Earnings ReportGap UpENZEnzo Biochem0.5768 of 5 stars$1.15flatN/A-16.9%$58.92M$33.34M0.00520Dividend AnnouncementXGNExagen4.1819 of 5 stars$2.43-3.2%$7.00+188.1%+46.2%$42.25M$56.66M-2.51220Upcoming EarningsBNRBurning Rock Biotech0.2789 of 5 stars$2.81-0.7%N/A-72.3%$28.79M$509.81M-0.591,390Gap DownRNLXRenalytix1.2279 of 5 stars$0.21+5.7%$3.00+1,348.6%-80.1%$17.18M$2.29M-0.53100Upcoming EarningsGap UpPMDPsychemedicsN/A$2.33+0.9%N/A-1.3%$13.53M$20.79M-2.99140Positive NewsBGLCBioNexus Gene LabN/A$0.36flatN/A-7.4%$6.47M$9.18M0.0030Positive NewsMDXHMDxHealth3.2244 of 5 stars$2.03-0.5%$7.33+261.2%-93.2%$3.17M$80.74M0.00300Upcoming Earnings Related Companies and Tools Related Companies Personalis Alternatives Sera Prognostics Alternatives Biodesix Alternatives Enzo Biochem Alternatives Exagen Alternatives Burning Rock Biotech Alternatives Renalytix Alternatives Psychemedics Alternatives BioNexus Gene Lab Alternatives MDxHealth Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGEN) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
